At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,135 enrolled
Drug / intervention
Plecanatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
In Brief
A Phase 3 clinical trial evaluating Plecanatide and Placebo for Irritable Bowel Syndrome Characterized by Constipation. Completed, enrolled 1,135 participants across 191 sites.
Detailed Summary
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionNov 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedJul 9, 2015
Enrollment StartJun 1, 2015
Primary CompletionNov 1, 2016
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.0 years ago
Interventions
Plecanatidedrug
Placebodrug